George D. Demetri

Dr. George D. Demetri is a Professor of Medicine at Harvard Medical School, Director of the Sarcoma Center at Dana-Farber Cancer Institute, and Director of the Ludwig Center at Dana-Farber/Harvard Cancer Center. He serves as Executive Director for Clinical and Translational Research at the Ludwig Institute for Cancer Research and holds the Quick Family Chair in Medical Oncology. His clinical focus centers on bone sarcomas, gastrointestinal stromal tumors (GIST), and soft tissue sarcomas.

Dr. Demetri's research interests span molecular targeted agents and signal transduction inhibitors for sarcoma treatment. His groundbreaking work established the foundation for using tyrosine kinase inhibitors as effective therapies for GIST, leading to FDA approval of imatinib mesylate (Gleevec). His research team pioneered differentiation therapy for liposarcomas targeting PPAR-gamma and developed novel agents like ET-743 derived from marine organisms. His work demonstrates how understanding sarcoma biology can translate into targeted treatments that significantly improve patient outcomes.

Analysis of Dr. Demetri's recent publications reveals a strong focus on immunotherapy approaches for sarcomas, particularly T-cell therapies targeting NY-ESO-1, and continued innovation in molecularly targeted treatments. His research spans rare sarcoma subtypes, biomarker identification, and real-world evidence generation for oncology drug development. The publications consistently emphasize precision medicine approaches tailored to specific molecular alterations in sarcomas.

• Focused Giving Program Award, Johnson and Johnson Foundation (1993)
• Emil J. Freireich Award in Clinical Cancer Research (2002)
• Claire W. and Richard P. Morse Research Award (2005)

Dr. Demetri leads a multidisciplinary research team that includes dedicated representatives from surgical oncology, radiation oncology, pathology, and other clinical arenas working closely with laboratory investigators. His work has secured significant funding for sarcoma research, particularly through the Ludwig Institute for Cancer Research. His leadership has established Dana-Farber as a global center for sarcoma treatment and research, with numerous clinical trials evaluating novel therapeutic approaches for these rare cancers.

As Director of the Sarcoma Center at Dana-Farber, Dr. Demetri oversees a comprehensive program that brings together experts across multiple disciplines to develop innovative treatments for sarcoma patients. His laboratory research focuses on translating basic biological discoveries into novel therapeutic approaches, with particular emphasis on signal transduction pathways in sarcomas. The center maintains strong collaborations with other major cancer centers globally to advance sarcoma research and treatment.